Blenrep(belantamab mafodotin)
Blenrep (belantamab mafodotin) is an antibody pharmaceutical. Belantamab mafodotin was first approved as Blenrep on 2020-08-05. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma.
Download report
Favorite
Case Study: Multiple Myeloma
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Belantamab mafodotin
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Blenrep | belantamab mafodotin-blmf | GSK | N-761158 DISCN | 2020-08-05 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| blenrep | Biologic Licensing Application | 2020-08-05 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
belantamab mafodotin, Blenrep, GlaxoSmithKline Intellectual Property Development Ltd. England | |||
| 2027-08-05 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9037 | Injection, belantamab mafodotin-blmf, 0.5 mg |
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 3 | 3 | — | — | — | 3 | |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 3 | 3 | — | — | — | 3 |
| Blood protein disorders | D001796 | 3 | 3 | — | — | — | 3 | ||
| Plasma cell neoplasms | D054219 | 3 | 3 | — | — | — | 3 | ||
| Paraproteinemias | D010265 | D47.2 | 3 | 3 | — | — | — | 3 | |
| Corneal diseases | D003316 | H18.9 | 3 | 3 | — | — | — | 3 | |
| Immunoglobulin light-chain amyloidosis | D000075363 | 1 | 2 | — | — | — | 2 | ||
| Plasmablastic lymphoma | D000069293 | C83.3 | — | 1 | — | — | — | 1 | |
| Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BELANTAMAB MAFODOTIN |
| INN | belantamab mafodotin |
| Description | Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.
|
| Classification | Antibody |
| Drug class | synthetic analogs of the dolastatin series; monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2050232-20-5 |
| RxCUI | 2387844 |
| ChEMBL ID | CHEMBL4298209 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15719 |
| UNII ID | DB1041CXDG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 588 documents
View more details
Safety
Black-box Warning
Black-box warning for: Blenrep
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
720 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more